NINDS Research Program Award (R35) and FAQs

The goal of the NINDS Research Program Award (RPA; RFA-NS-18-032), which uses the R35 funding mechanism, is to allow an investigator whose record of research achievement demonstrates his or her ability to make major contributions to neuroscience, the freedom to embark on ambitious, creative, and/or longer-term research projects, without the constraints of specific aims. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a maximum level of $750,000 direct costs per year.

We invite you to read about the exciting work of our past R35 recipients, as well as a new message from NINDS Director, Dr. Walter Koroshetz encouraging R35 applications, in particular from early career and diverse candidates.

If you have any questions about the NINDS Research Program Award (RPA) or about whether you are a good candidate for the award, please reference the FAQs below and/or contact your program director.

 

NINDS Research Program Award Frequently Asked Questions

  1. Funding Opportunity Description
  2. Eligibility Information
  3. Application and Submission Information
    1. Research Plan
    2. Budget
    3. Senior/Key Personnel
  4. Review Information
  5. Award Administration Information (Including Funding Restrictions in Section IV.2 of the FOA)

I. Funding Opportunity Description

Q.  What is the NINDS Research Program Award and what is its purpose?
A.  The Research Program Award (RPA) is a funding mechanism being used by the NINDS to provide support for a single investigator and his/her laboratory as a whole, rather than on a project-by-project basis. Its purpose is to support all NINDS mission-relevant research in a laboratory through a single grant award that will be up to eight years in duration.

Q.  What distinguishes the RPA from traditional NIH programs?
A.  The RPA is intended to provide an investigator with funding stability and increased flexibility to pursue new research directions, and enable longer-range research goals. Other differences include: a reduced level of detail required in the application, including the elimination of specific aims; differences in the review process and review criteria to emphasize the impact of the work and to de-emphasize details of the approach.

Q.  How can I decide if RPA is right for my circumstances?
A.  Ask yourself how much time and effort it takes you to maintain the current NINDS funding of your laboratory through multiple, separate grant applications. Decide whether consolidation of your projects at something close to your average level of NINDS support is worth the advantages provided by the RPA program, which includes up to eight years of stable funding.  Consult with your current Program Director for additional guidance.

Q.  How much time/effort must recipients devote to RPA? How many calendar months?
A.  By replacing all or most of an investigator’s NINDS funding, the research supported by an RPA should be the major focus of the PD/PI’s laboratory or research group. Therefore, the PD/PI must devote at least 6 person months (i.e., the equivalent of 50% effort on for a full-year appointment, 66.67% on a 9-month appointment, or 100% on a 6-month appointment) to the RPA throughout the duration of the award period.   PDs/PIs will be expected to renegotiate their time and effort on other non-NINDS awards if necessary.

Q.  What scientific areas of research are appropriate for support by RPA?
A.  Any research area within the mission of NINDS is eligible for support using the RPA award.  However, some types of research might be more suitably supported through a traditional R01 or other grant mechanism that requires more specific methodological detail or programmatic oversight (e.g., clinical trials, advanced translational research). NINDS strongly encourages applicants to speak with NINDS program staff to help determine if a different mechanism is better suited to the proposed research area. The RPA is neither appropriate for the support of clinical trials designed to answer specific questions about the safety, tolerability, efficacy, effectiveness, clinical management, and/or implementation of pharmacologic, behavioral, biologic, surgical, or device (invasive or non-invasive) interventions nor is it appropriate for research that has been traditionally supported by another NIH Institute or Center, even when combined as part of a larger research program.

Q.  Can technology development be included or is the award only for hypothesis-driven research?
A.  Yes. Technology development can be an essential part of any research program and hypothesis-driven science is only one way of approaching a research problem. However, applicants should contact NINDS staff to determine if the R35 is the most appropriate mechanism of support, as NINDS has a number of Funding Opportunities that specifically support tool and technology development and dissemination.

Q.  Can you clarify how much flexibility is meant by "flexibility to pursue new research directions"?
A.  With an RPA, PD/PIs will be allowed to pursue new research objectives and problems and to modify their model systems or approaches, but will be expected to work with program staff to ensure that the program remains within the mission of the NINDS and compliant with NIH policy.

Q.  What will be considered in scope and what would be out of the scope of an RPA?
A.   Work that migrates fully into the mission of another NIH institute or center would be considered out of scope and not appropriate for pursuit through the RPA.  Changes in scope could include, for example, the addition of or a change in the approved use of human subjects, vertebrate animals, select agents or human embryonic stem cells (hESCs). Such changes require prior approval by NINDS before the work is initiated. However, such changes in scope can be approved with appropriate documentation. Please refer to the NIH Grants Policy Statement for additional guidance (NIH GPS 8.1.2.5).

Q.  How many RPAs does NINDS expect to award in FY 2019?
A.  This depends on the number and cost of meritorious applications. NINDS estimates that as many as 30 awards will be made.

top

II. Eligibility Information

Q.  Who is eligible to apply?
A.  
This FOA targets all investigators who received one or more R01-equivalent awards (defined here as R00, R01, R37, R56, DP1 or DP2 awards) from NINDS for at least 5 years, with support for one or more of their awards expiring in FY 2018 or FY 2019 (October 1, 2017 - September 30, 2019). For the purposes of this announcement only investigators with grants meeting the above criteria are eligible to apply.  Examples of activities that are not considered R01 equivalents include U01, P01/P50s.

a.     My grant is on a No Cost Extension (NCE). Am I still eligible to apply?  Grants in a no cost extension remain active and expire at the end of the no cost extension period; however only one NCE is permitted to establish eligibility.  A grant cannot be in a 2nd NCE, nor can two NCEs be used to demonstrate 5 years of continuous NINDS funding.
b.    At some point in the previous five years, my grant was either in a NCE or I had an NINDS R56 award.  Do I still qualify has having had continuous NINDS support for the last five years?  Yes. Continuous support from NINDS on an active R01 equivalent grant (including those on a NCE or R56) qualifies as five years of consecutive support.
c.    Why are U01s being excluded from eligibility consideration?   U01s involve substantial NIH staff involvement which would be difficult to incorporate into an RPA.
d.    One of my current grants is equivalent in budget and scope to an R01 grant (e.g., U01, U10, P50, P01, a sub-project of a Program Project Grant, etc.) but is not the specified R01-equivalent type identified in the FOA. Am I eligible to apply?  No.  R01-equivalent awards are limited to only the R00, R01, R37, R56, DP1, and DP2 mechanisms.
e.    If I am a PD/PI on a multi-PD/PI R01, am I eligible to apply?  Yes, but investigators who receive an RPA will be required to relinquish their other NINDS funding. In the case of multiple-PD/PI awards, they will relinquish their financial interest in the MPI award but will be expected to continue the collaboration according to the approved leadership plan, using support from RPA.

Q.  What is the definition of a PD/PI on a NINDS grant in the context of “received continuous R01 or R01 equivalent grant support from NINDS for at least the past 5 years”?
A.  
You must be listed as the PD/PI on the Notice of Award (NoA) of an NINDS grant to be considered the PD/PI. You must have been funded continuously as PD/PI in each of the past five consecutive years at the time of application submission.

Q.  Is there a separate FOA for so-called “emerging” or early career investigators?
A.  No.  Investigators at all career stages that meet the eligibility requirements are encouraged to apply for the RPA.  In developing a pay plan for the RPA, NINDS will seek to ensure that award recipients reflect a diversity of career stages.

Q.  Are women and members of underrepresented groups encouraged to apply?
A.  Yes. NINDS places a high value on maintaining a diverse biomedical workforce and strongly encourages women and members of underrepresented groups who meet the eligibility requirements to apply for an RPA.  In developing a pay plan for the RPA, NINDS will seek to ensure that RPA award recipients are diverse not only with respect to scientific approach and area of study, but also with respect to investigator background.

Q.  May two or more scientists apply as a team for an NINDS RPA?
A.  No.  This FOA is intended to provide support for the research program of a single independent, investigator.

Q.  Are scientists in the NIH intramural research program eligible to apply?
A.  
No.  NIH intramural research program scientists are not eligible to apply. A RPA application can include collaboration with an intramural scientist, but no funds can be provided to the intramural laboratory via the RPA.

Q.  Are individuals who have support from sources other than NINDS eligible to apply?
A.  
Yes. Individuals may have support from other NIH components or from other sources, provided they meet all other eligibility requirements and are able to commit at 6 person months (i.e., the equivalent of 50% effort on for a full-year appointment, 66.67% on a 9-month appointment, or 100% on a 6-month appointment) to the RPA throughout the duration of the award period.

Q.  Are Howard Hughes Medical Institute investigators eligible to apply for RPA? What about individuals with other types of substantial, unrestricted research support?
A.  
Yes. HHMI investigators are eligible to apply for RPA, provided they are able to commit 6 person months (i.e., the equivalent of 50% effort on for a full-year appointment, 66.67% on a 9-month appointment, or 100% on a 6-month appointment) to the RPA throughout the duration of the award period. The relationship between the work supported by another organization and the work to be supported by NINDS must be distinct, and it must be clearly explained how the funding provided by the RPA will impact your research program.  Investigators with other types of substantial, unrestricted laboratory support will be similarly considered on a case-by-case basis, however, lower funding priority may be given to applicants with significant unrestricted research support.

Q.  Can I submit an application for continuation of my current NINDS grant support and apply for RPA at the same time?
A.  
Yes. You may submit a competing continuation in parallel to your R35 application; however if both applications receive meritorious scores only one of these applications will supported

Q.  The initial four years of support on my Javits award expire in FY18 or FY19.   Am I eligible to submit an R35?
A.  
Yes.  You can submit an RPA application concurrently with your Type 4 extension application.  Your RPA application should incorporate the work done through your Javits award.

Q.  If I have an appointment at more than one institution, can I apply for a separate RPA through each institution?
A.  
No. An investigator can only receive one RPA award, which should be submitted by the institution where he or she primarily conducts his or her research program.

Q.  Can I get a definitive determination of my eligibility prior to submitting an application to this Request for Application (RFA)?
A.  
No. NINDS staff can give you advice on eligibility; however, applications are evaluated for eligibility by the Receipt and Referral Office at the NIH Center for Scientific Review based on the criteria stated in the FOA.

top

III. Application and Submission information

Q.  Is there a limit on the number of applications that can be submitted by an institution? By a PD/PI?
A.  
There is no limit on the number of applications that can be submitted by an institution.  A PD/PI may submit only one application for an RPA.

Q.  Can I get advice on my ideas for submission of a RPA application?
A. 
You may discuss your ideas with the program contact named in the FOA or with the program director(s) who administers your current NINDS applications and awards.

Q.  What format should the application follow?
A.  
Follow the instructions in the SF424 R&R application guide as modified by the instructions in the FOA.  Please note that the RPA application has additional requirements in the following sections:

  • PHS 398 Research Plan [Research Strategy]
  • R&R Budget
  • SF424(R&R) Senior/Key Person Profile
  • SF424(R&R) Other Project Information
RESEARCH PLAN

Q.  Why is the Research Strategy Section only six pages?
A.  
Because the goal of RPA is to focus investigator and reviewer attention on the higher level questions about significance and impact of the research program, details in the research plan can be reduced. 

Q.  What became of the specific aims section of the grant application?
A.  
Specific aims are not required in order to focus the application on the impact of an investigator’s entire NINDS supported research program. 

Q.  Should I submit letters of support?
A.  
The application must include a letter from the institution’s Authorized Organizational Official (AOR) indicating that they are aware of and accept the condition that other NINDS research awards must be relinquished as a condition of receiving a RPA and providing a statement that if chosen to receive an award, the PD/PI will commit a minimum of 6 person months (as described above) throughout the duration of the RPA. Letters of support should be included for all collaborators.  

top

BUDGET

Q.  What is the maximum allowable budget?
A.  Applicants may request up to a maximum of $750,000 direct costs per year; however, the requested RPA budget must be commensurate with the investigator’s recent level of NINDS support.

Q.  How should I determine my RPA budget?

A.  RPA budget MUST be based on your level of recent support. That level of support must be calculated using the average direct cost total for the 4 most recent years (i.e. 2014 – 2017 or 2015 – 2018, whichever is greater) from all awarded NINDS research grants of the type that will be folded into the R35 award; it should not include funding that is exempt from R35 fold in (see Section 1, Overview). Calculations should use awarded direct costs (including administrative cuts), and in the case of MPI/MPD awards or multi-component grants/cooperative agreements, should only include the amount of the total award that is attributable to the applicant PI/PD. Moreover, in the case of multi-component grants/cooperative agreements, the budget should not incorporate funds attributable to cores, as these funds will not be folded into the RPA. Please note that pending support should not be considered when developing an RPA budget, even if such applications should get funded between the R35 submission and award. Although the RPA mechanism is not intended to support the expansion of an investigator’s current level of NINDS funding, RPAs will be awarded for no less than $350K DC. Barring this exception, only in very rare and extremely well-justified circumstances (e.g. an investigator is still within the growth phase of their careers) will awards exceed the most recent 4 year funded average of NINDS grants subject to be folded in. Applications submitted with budgets of more than 20% over the 4 year average described above will be considered non-compliant to this FOA and will be withdrawn prior to review. PDs/PIs are encouraged to discuss their proposed budgets / projects with NINDS program staff prior to submission and should provide detailed evidence supporting their proposed request in the budget justification section (e.g. table calculating 4 year average of direct costs, including grant numbers with awarded direct costs for each year; for example see NINDS Research Program Award (R35) and FAQs). Year one of the R35 award will be offset by any funds disbursed in the same FY from awards that will be folded into the RPA.

Q.  Could you provide a template for calculating and providing my budget?

R35 Budget Request Format template

Q.  I am supported by a single NINDS modular R01 and would like to apply for and RPA; however I don’t want my application to be withdrawn for being over the 20% threshold. How should I proceed?
A.  No RPA will be awarded for less than $350K DC.  Applicants traditionally supported by 1 modular R01 should submit an R35 budget for this amount (with appropriate justification for the increase in budget).

Q.  Will salary or other funds I receive as a co-investigator on another PD/PIs NINDS research grant be counted toward the RPA budget?  May I continue to receive this support if I am awarded an RPA?
A.  Support as a co-investigator on another PI/PD’s grant will not be counted nor folded into the RPA budget. Such support may continue through the end of the existing grant period.  It is expected that the total amount of future sub-contracts will not significantly exceed the amount of support that is currently held by the applicant. Sub contracts should not be used to circumvent the budget limits of the RPA.

Q.  I have an application that received a score within the NINDS payline that was reviewed by the NINDS Council at the September 2018 meeting. How will this To Be Paid grant impact my R35 budget if it receives a fundable score?
A.  No pending support (e.g. grants going to September Council 2018 or later) will be used to determine your RPA budget.  At such time that you are offered an R35 award, you should weigh the benefits of 8 years of stable funding against the potential peaks and valleys associated with shorter term awards.  

Q.  What grants should I include when determining an appropriate budget for my research program?
A.  All grants subject to consolidation into the R35 should be used to calculate your budget.  This includes all NINDS supported RPGs, P01s, P50, and other Center awards.  There are a number of NINDS activities that are excluded from consolidation and that should not factor into the determination of your R35 budget.  These include:

  • Contracts;
  • SBIR/STTR grants or cooperative agreements;
  • Conference grants;
  • Grants or cooperative agreements that exclusively support research resources (e.g. P30, R24 or U24 awards);
  • Grants or cooperative agreements supporting training, diversity, or workforce development;
  • Grants or cooperative agreements supporting clinical trials submitted in response to NINDS clinical trials required FOAs;
  • Grants or cooperative agreements submitted in response to the NINDS IGNITE, CREATE, or Translational Neural Devices Programs;
  • Grants or cooperative agreements submitted in response to BRAIN Initiative FOAs


Q.  How do I factor in my contribution from P01s, P50s or other multi-component awards when determining my RPA budget?
A.  When determining your RPA budget, you should only include the monies directed towards your research efforts on the MPI grant. In the case of P01s or Center awards, you should not include funds directed to either administrative or scientific cores; these funds will not be rolled into the RPA and will remain associated with the multi-component project.

Q.   How do I build in annual inflationary increases into my RPA budget if I am asking for the $750K maximum?
A.   All R35 awards will be made with flat budgets.  Although there may be an opportunity for a modest increase to your award amount following the 5 year administrative checkpoint, this is not guaranteed, and should not be expected.

Q.  My grant was in a no cost extension for one year between 2014 and 2017 (or 2015 – 2018).  How do I factor this year into my four year average when determining my R35 budget? 
A.  An NCE is an extension of time, and not money.  As no new funds were awarded during your NCE year, you should include 1 year of zero dollars in your calculation.  For example, if you had a non-modular R01 with a budget of $585,000 DC that was awarded with a 17.5% administrative cut (i.e. $482,625 DC) in FY14, FY15, and FY16, and that grant was in an NCE for FY17, your 4 year average would be $386,100 DC.


Q.  In the absence of specific aims, how do I conceptualize and prepare a non-modular budget?
A.  
The requested budget should include information for anticipated costs related to accomplishing the Research Strategy proposed in the application.  Given that the NINDS RPA will generally fold in an investigator’s current research projects, the requested budget should reflect the budgetary needs for the current research.

Q.  Can I request money for equipment in the budget?
A.  
Yes. You may request money for equipment in the first year and in any subsequent years with appropriate justification. Such requests should be accommodated within a budget that is commensurate with the overall NINDS grant support of the laboratory in recent years. This is not intended as a mechanism to acquire "big-ticket" items that may be covered under instrument-specific funding opportunities.

Q.  Can I continue to work with my current collaborators, including foreign collaborators?
A.  
Yes. NINDS strongly endorses collaborative research. However, as the RPA concept is based on the idea that NINDS will provide support to individual investigators and their laboratories, Multi-PD/PI applications are not appropriate for the RPA. Most collaborators will be expected to work together because of their mutual interest in a problem. This applies to foreign collaborations as well. NINDS will accept applications with a foreign collaboration, but will likely not provide significant funding for foreign consortium arrangements.

Q.  Can I include a consortium contract for a collaborator?
A.  
Yes, but such requests must be extremely well justified, and in general collaborations should be supported by resources provided by both parties, rather than through a subcontract. In rare circumstances, a letter from the subcontract PD/PI should be included, making it clear why he or she cannot participate in collaborative research with the PD/PI without support from RPA.

top

SENIOR / KEY PERSON PROFILE

Q.  Who, if anyone, in addition to the PD/PI should be listed as "key personnel"?
A.  
Key personnel include any other individuals who contribute to the scientific development or execution of a project in a substantive, measurable way, whether or not they receive salaries or compensation under the grant. Typically, these individuals have doctoral or other professional degrees, although individuals at the master's or baccalaureate level may be considered senior/key personnel if their involvement meets this definition. Consultants and those with a postdoctoral role also may be considered senior/key personnel if they meet this definition. Senior/key personnel must devote measurable effort to the project whether or not salaries or compensation are requested. "Zero percent" effort or "as needed" are not acceptable levels of involvement for those designated as senior/key personnel.  See https://grants.nih.gov/grants/policy/senior_key_personnel_faqs.htm#1658 for additional information on the use of key personnel in your application.

Q.  How will support of other senior/key personnel (co-PD/PIs) be considered?
A.  
Senior/key personnel who are independent investigators can contribute effort toward RPA. They may receive support from the award, but only if they do not also receive support from their own RPA award.

Q.  What may I include in the appendix?
A.  
Appendix materials are limited to those allowed by NIH Policy.  See NOT-OD-16-129.

Q.  Who will be the scientific point of contact for my RPA application?
A.  
Dr. David Owens (Acting Deputy Director of Extramural Research, NINDS) will serve as the initial point of contact for questions about the FOA.  Should you wish to discuss scientific aspects of your application, you should contact your current NINDS program officer. Once applications are received, they will be referred to the most relevant program official based on internal NINDS referral procedures and guidelines. The name and contact information for the program official will appear at the top of the summary statement.

top

IV. Review Information

Q.  How will responses to this FOA be reviewed?
A.  Review will be by special emphasis panels organized by the NINDS Scientific Review Branch. The name and contact information for the scientific review official assigned to the application will be posted in the Commons.

Q.  What is the timeline for application, review and award?
A.   
Applications received by July 2018 will be reviewed in November 2018 for consideration by the National Advisory Neurological Disorders and Stroke Council in January 2019, with the earliest possible awards beginning in April 2019.

Q.  Will the reviewers have expertise in the subject area of my application?
A.  
Yes. NINDS will ensure that reviewers have the relevant expertise to review the application, bearing in mind that RPA is intended to support a broad program of research and the breadth of research areas that are encompassed by the NINDS mission. Thus, reviewers will be expected to bring a broad perspective rather than detailed expertise.

Q.  How will the review process for RPA differ from that for regular R01 research grant applications?
A.  
Reviewers will be asked to provide a single overall impact score and not to provide individual criterion scores. This is intended to shift emphasis away from details of the application and the approach, and to emphasize the potential impact of the investigator's research program on the field. Reviewers will be provided with information about the applicant’s funding history and asked to comment on whether or not the budget requested in the RPA reflects the current scope of the investigator’s research support from NINDS.

Q.  How do the review criteria differ from those for a regular R01 research grant application?
A.  
The review criteria are the same, but the wording has been modified to emphasize the review of the investigator's overall NINDS-relevant research program rather than a specific, narrowly-focused project with highly tailored specific aims. Reviewers should emphasize RPA-specific aspects of significance, investigator qualifications, innovation, approach and environment.

Q.  How will the study section arrive at a budget recommendation?
A.  
Reviewers will be asked to consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed work. It is anticipated that reviewers will consider the past productivity of the investigator's laboratory in areas relevant to the NINDS mission, given the resources at the laboratory's disposal, evidence of efficient use of funds in the past and likelihood of efficient use of funds in the future. Reviewers will be provided with information about the applicant’s funding history and asked to comment on whether or not the budget requested in the RPA reflects the current scope of the investigator’s research support from NINDS.  If the proposed budget exceeds the current (2014 – 2017 or 2015-2018) level of support, reviewers will consider whether there are exceptional circumstances that justify the increased level of support.  Applications requesting budgets more than 20% over the 4 year average will be considered non-compliant to this FOA and will not be reviewed.

Q.  Can I appeal the review of my RPA application?
A.  
No. This FOA is a one-time request for applications. Therefore, be sure to inform NINDS of any potential reviewer conflicts in a cover letter included with the application at the time of submission.

Q.  If my application for RPA is not funded, will I be able to prepare a resubmission?
A.  
No, but you may be eligible to submit a new application to another RPA FOA in future fiscal years.

Q.  How does the NIH Special Council Review policy apply to RPA?
A.  
In August 2012, NIH implemented a policy whereby applications from investigators whose overall research support (excluding the pending application) exceeds $1 million per year in direct costs, would be subjected to additional scrutiny by the National Advisory Neurological Disorders and Stroke Council prior to funding.  RPA funding will be factored in to the calculation of an investigator’s “research support” should additional NIH funding be sought.

Q.  What will be Council involvement in the second level peer review of RPA applications?
A.  
RPA applications in response to this FOA will be made available to the National Advisory Neurological Disorders and Stroke Council in the same way as other applications. Council members will be free to comment on any application and will vote to approve applications for potential funding.

top

V. Award Administration Information (Including Funding Restrictions in Section IV.6 of the FOA)

Q.  How will NINDS fold current multiple-PD/PI awards and subprojects of multicomponent awards such as P01s and P50s into the new R35 award?
A.  Investigators who receive an RPA will be required to relinquish their other NINDS funding. In the case of multiple-PD/PI awards, they will relinquish their financial interest in the award but will be expected to continue the collaboration with support from RPA. This transition may be made at the end of a current budget period. The budget of the R01, P01, P50, etc. would be appropriately adjusted to reflect the cessation of support from the multiple-PD/PI award whenever that occurs. Investigators supported by RPA are expected to continue as associated investigators of the continuing P01 or P50 and thus be expected to interact with the other subproject investigators and to have access to the P01 or P50 cores.

Q.  Will a change of PI/PI be allowed?
A.  
A permanent change of PD/PI will not be allowed, as RPA is intended to support the research program of a single independent investigator. A temporary change may be allowed with prior approval under circumstances such as sabbatical leave, medical conditions, disability or personal or family situations.

Q.  What happens if the PD/PI becomes unable to carry out the duties as PD/PI or will be absent for more than 3 months at a time for any reason?
A.  
Standard NIH and NINDS policies will be applied.

Q.  Will a change of grantee institution be allowed?
A.  
Standard NIH and NINDS policies will be applied, provided that the receiving institution agrees to all of the required terms of the RPA.

Q.  What, if anything, will be different about the annual reporting required for RPA?
A.  
Annual reports will be required using the Research Performance Progress Report (RPPR). Additional FOA specific requirements will be indicated in the Notice of Award.

Q.  What changes will require prior approval?
A.  
There are no changes to standard NIH policy on prior approval requirements. Prior approval is needed for the following:

  • A change in scope including but not limited to, a change from the approved used of vertebrate animals or involvement of human subjects, select agents or human embryonic stem cells
  • Late notification of an initial no cost extension
  • Change in status of the PD/PI or senior/key personnel named in the Notice of Award
  • Change in grantee organization or organization status

Q.  How will NINDS manage overlap with other grants that may be awarded after the initial RPA?
A.  
Changes in other support should be reported in the RPPR. The relationship between other support and work supported by RPA should be explained. NINDS will assess whether there is sufficient scientific and budgetary overlap to warrant adjustment of the RPA.

Q.  Will carryover of an unobligated balance from one budget period to another be permitted?
A.  
Standard NIH and NINDS policies will be applied.

Q.  Will RPAs be eligible for administrative supplements? Competitive supplements?
A.  
RPAs will be eligible for Research Supplements to Promote Diversity in Health-Related Research and other types of administrative supplements, including equipment supplements that may be offered by NINDS through notices in the NIH Guide for Grants and Contracts. Competitive supplemental applications (revisions) may be accepted in response to FOAs that may be issued in the future to support increases in scope beyond the ability of the investigator to accommodate through reprioritization of their existing resources (e.g., addition of human subjects); however, generally awardees will be expected to reallocate existing resources to accommodate new research directions.

Q.  How will NINDS handle changes in senior/key personnel on a RPA?
A.  
Senior/key personnel named in the notice of award may be replaced or eliminated from the budget with prior approval. Applicants should report such changes in their annual progress reports and should include plans for the utilization of the funds to support the overall effort of the laboratory. Persons not named in the notice of award can be replaced without prior approval.

Q.  How will receipt of support from RPA effect the eligibility of co-PD/PIs to receive other grants?
A.  
Senior/key personnel other than the PD/PI may receive support from other awards, including other RPA awards on which they are also not the PD/PI. Independent investigators who receive any support from more than one NINDS grant are encouraged to consider consolidating their support by applying for a RPA application when they become eligible under future FOAs.

top